- $1.22bn
- $758.00m
- $656.32m
- 76
- 46
- 53
- 60
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 39.52 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.71 | ||
| Price to Tang. Book | 1.31 | ||
| Price to Free Cashflow | 37.61 | ||
| Price to Sales | 1.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -10.08% | ||
| Return on Equity | -7.58% | ||
| Operating Margin | -28.54% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 388.54 | 513.7 | 555.5 | 665.07 | 656.32 | 593.34 | 625.28 | -3.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +68.72 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Azenta, Inc. is a provider of life sciences solutions worldwide. The Company provides a full suite of cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions globally. The Company's segments include Sample Management Solutions and Multiomics. Its Sample Management Solutions segment offers end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Company's Multiomics segment includes its genomic services business, which advances research and development activities by providing gene sequencing, synthesis, editing and related services. The Company's brands include GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
Directors
- Joseph Martin NEC (74)
- Stephen Schwartz PRE (62)
- Lindon Robertson CFO (60)
- Matthew McManus COO
- Kimberly Crowley CHO (44)
- Jason Joseph SVP (51)
- Robin Vacha SVP (46)
- William Montone SVP (69)
- Linda De Jesus SVP (50)
- David Gray SVP (56)
- Vandana Sriram CAO (48)
- Frank Casal IND (67)
- Robyn Davis IND (60)
- Erica Mclaughlin IND (45)
- Krishna Palepu IND (67)
- Michael Rosenblatt IND (74)
- Alfred Woollacott IND (75)
- Mark Wrighton IND (72)
- Ellen Zane IND (70)
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 14th, 1994
- Public Since
- February 2nd, 1995
- No. of Shareholders
- 455
- No. of Employees
- 3,000
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 45,695,591
- Address
- 200 Summit Drive, 6Th Floor, BURLINGTON, 01803
- Web
- https://www.azenta.com/
- Phone
- +1 9782622400
- Contact
- Sara Silverman
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for AZTA
Q2 2025 Azenta Inc Earnings Release
Q3 2025 Azenta Inc Earnings Release
Similar to AZTA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Azenta share price?
As of Today at 19:27 UTC, shares in Azenta are trading at $26.73. This share price information is delayed by 15 minutes.
How has the Azenta share price performed this year?
Shares in Azenta last closed at $26.73 and the price had moved by -48.1% over the past 365 days. In terms of relative price strength the Azenta share price has underperformed the S&P500 Index by -52.09% over the past year.
What are the analyst and broker recommendations for Azenta?
The overall consensus recommendation for Azenta is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Azenta dividend yield?
Azenta does not currently pay a dividend.
Does Azenta pay a dividend?
Azenta does not currently pay a dividend.
When does Azenta next pay dividends?
Azenta does not currently pay a dividend.
How do I buy Azenta shares?
To buy shares in Azenta you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Azenta?
As of the previous close price of $26.73, shares in Azenta had a market capitalisation of $1.22bn.
Where are Azenta shares listed?
Here are the trading details for Azenta:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AZTA
What kind of share is Azenta?
Based on an overall assessment of its quality, value and momentum Azenta is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Azenta share price forecast for 2025?
The analyst consensus target price for shares in Azenta is $49.33. That is 84.55% above the last closing price of $26.73.
Analysts covering Azenta currently have a consensus Earnings Per Share (EPS) forecast of $0.49 for the next financial year.
Find out moreWhat is the trend in the Azenta share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Azenta. Over the past six months, its share price has underperformed the S&P500 Index by -31.07%.
As of the last closing price of $26.73, shares in Azenta were trading -41.86% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Azenta PE Ratio?
The Azenta PE ratio based on its reported earnings over the past 12 months is 39.52. The shares last closed at $26.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Azenta?
Azenta's management team is headed by:
- Joseph Martin - NEC
- Stephen Schwartz - PRE
- Lindon Robertson - CFO
- Matthew McManus - COO
- Kimberly Crowley - CHO
- Jason Joseph - SVP
- Robin Vacha - SVP
- William Montone - SVP
- Linda De Jesus - SVP
- David Gray - SVP
- Vandana Sriram - CAO
- Frank Casal - IND
- Robyn Davis - IND
- Erica Mclaughlin - IND
- Krishna Palepu - IND
- Michael Rosenblatt - IND
- Alfred Woollacott - IND
- Mark Wrighton - IND
- Ellen Zane - IND